logo

For the Inventor, By the Inventor

Hamilton, Bermuda

Actinium Pharmaceuticals, Limited


USPTO Granted Patents = 22



Forward Citations = 45

Loading Chart...
Loading Chart...

23 inventors (with patents filed for the assignee):

goldMedal Josue Manuel Moreno Bermudez (6 out of 6 patents)

silverMedal Dragan Cicic (5 out of 5 patents)

bronzeMedal Kaushik J Dave (4 out of 12 patents)

4.  Richard Henkelmann (4 out of 4 patents)

5.  Eva Kabai (4 out of 4 patents)

6.  Shubh D Sharma (3 out of 61 patents)

7.  Andreas Turler (3 out of 3 patents)

8.  Ernst Huenges (3 out of 3 patents)

9.  Maurits W Geerlings (2 out of 2 patents)

10.  Mark Berger (2 out of 2 patents)

11.  Le-Cun Xu (2 out of 2 patents)

12.  Denis Beckford Vera (2 out of 2 patents)

13.  Jaime Simon (1 out of 70 patents)

14.  Dale Lincoln Ludwig (1 out of 12 patents)

15.  Mark Harfensteller (1 out of 7 patents)


22 patents:

1. 12410249 - Low dose antibody-based methods for treating hematologic malignancies (2025-09-09),
2. 12133849 - Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic (2024-11-05),
3. 12083192 - Methods for treatment of patients with myelodysplastic syndromes (2024-09-10),
4. 11981741 - Humanized anti-CD45 antibodies (2024-05-14),
5. 11975081 - Bifunctional chelators and conjugates (2024-05-07),
6. 11964948 - Bifunctional chelators and conjugates (2024-04-23),
7. 11912780 - Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies (2024-02-27),
8. 11844799 - Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic (2023-12-19),
9. 11406724 - Stabilized radiolabeled anti-CD45 immunoglobulin compositions (2022-08-09),
10. 11364235 - Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic (2022-06-21),
11. 11292835 - Low dose antibody-based methods for treating hematologic malignancies (2022-04-05),
12. 11241512 - Stabilized radio-labeled anti-CD45 immunoglobulin compositions (2022-02-08),
13. 10736975 - Infusion administration of conjugated monoclonal antibodies (2020-08-11),
14. 10420851 - Stabilized radiolabeled anti-CD45 immunoglobulin compositions (2019-09-24),
15. 9790573 - Method for purification of 225AC from irradiated 226RA-targets (2017-10-17),
Actinium Pharmaceuticals, Limited is a biopharmaceutical company focusing on the development and commercialization of targeted therapies for patients with unmet medical needs. They are dedicated to improving the lives of cancer patients by developing innovative treatments using their proprietary technology platform. Actinium Pharmaceuticals is committed to advancing the field of precision medicine through their research and development efforts.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
22 Patents

#28 in Hamilton

#31 in Bermuda

#27,908 in the World

...
Hamilton, Bermuda

Actinium Pharmaceuticals, Limited

Forward Citations = 45

23 inventors:

goldMedal Josue Manuel Moreno Bermudez (6 out of 6 patents)

silverMedal Dragan Cicic (5 out of 5 patents)

bronzeMedal Kaushik J Dave (4 out of 12 patents)

4.  Richard Henkelmann (4 out of 4 patents)

5.  Eva Kabai (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com
Loading…